JP2002528140A - ヒトｐａｎ−ｈｃｖヒトモノクローナル抗体 - Google Patents

ヒトｐａｎ−ｈｃｖヒトモノクローナル抗体

Info

Publication number
JP2002528140A
JP2002528140A JP2000579790A JP2000579790A JP2002528140A JP 2002528140 A JP2002528140 A JP 2002528140A JP 2000579790 A JP2000579790 A JP 2000579790A JP 2000579790 A JP2000579790 A JP 2000579790A JP 2002528140 A JP2002528140 A JP 2002528140A
Authority
JP
Japan
Prior art keywords
hcv
cbh
antibody
protein
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000579790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002528140A5 (https=
Inventor
ケイ．エイチ．ファウング スティーブン
ジー．ハドロック ケニス
Original Assignee
ザ ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ filed Critical ザ ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ
Publication of JP2002528140A publication Critical patent/JP2002528140A/ja
Publication of JP2002528140A5 publication Critical patent/JP2002528140A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000579790A 1998-11-05 1999-10-29 ヒトｐａｎ−ｈｃｖヒトモノクローナル抗体 Pending JP2002528140A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18705798A 1998-11-05 1998-11-05
US09/187,057 1998-11-05
PCT/US1999/025711 WO2000026418A1 (en) 1998-11-05 1999-10-29 Human pan-hcv human monoclonal antibodies

Publications (2)

Publication Number Publication Date
JP2002528140A true JP2002528140A (ja) 2002-09-03
JP2002528140A5 JP2002528140A5 (https=) 2006-12-14

Family

ID=22687437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000579790A Pending JP2002528140A (ja) 1998-11-05 1999-10-29 ヒトｐａｎ−ｈｃｖヒトモノクローナル抗体

Country Status (5)

Country Link
US (1) US6692908B1 (https=)
EP (1) EP1127170A4 (https=)
JP (1) JP2002528140A (https=)
AU (1) AU1462300A (https=)
WO (1) WO2000026418A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501594A (ja) * 2006-08-25 2010-01-21 ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド 組換えｈｃｖｅ２糖タンパク質
JP2010518854A (ja) * 2007-02-21 2010-06-03 ユニバーシティー オブ マサチューセッツ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
JP4958773B2 (ja) * 2005-06-02 2012-06-20 松森　　昭 Ｃ型肝炎ウイルス感染の診断、予防および治療方法
JP5608087B2 (ja) * 2008-09-30 2014-10-15 東レ株式会社 Ｃ型肝炎ウイルスのエンベロープタンパク質２に結合する抗体及びそれを用いたｃ型肝炎ウイルスの遺伝子型の同定方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5285899A (en) 1998-07-21 2000-02-14 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
DE60034884T2 (de) * 1999-06-04 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen
US7084266B1 (en) 1999-06-04 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cloned genome of infectious hepatitus C virus of genotype 2A and uses thereof
EP1245236A4 (en) * 1999-12-28 2004-09-22 Sumitomo Pharma PROPHYLACTICS AND THERAPEUTICS FOR TREATING CHRONIC HEPATITIS
EP1256348B1 (en) * 2000-02-14 2012-05-02 Mitsubishi Tanabe Pharma Corporation Remedies for hepatitis c
IL137522A (en) * 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu Human monoclonal antibody against hepatitis c virus e2 glycoprotein
CA2429946A1 (en) * 2000-12-01 2002-07-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
ATE425187T1 (de) 2001-01-12 2009-03-15 Molecules Of Man Ab Materialien und methoden zur behandlung von hepatitis c
CA2480464A1 (en) * 2001-04-03 2002-10-17 Rapid Medical Diagnostic Corporation Anti-idiotypic antibody and its use in diagnosis and therapy of hepatitis c virus related diseases
US7179600B2 (en) 2001-04-12 2007-02-20 Biocore Co., Ltd. Oligonucleotide chip composition and a method for analyzing a hepatitis C virus genotype using the composition
JP4781628B2 (ja) * 2001-12-05 2011-09-28 センス プロテオミック リミテッド 対立遺伝子改変体のためのタンパク質アレイおよびその使用
EP1572720A4 (en) 2002-05-24 2008-12-24 Nps Allelix Corp PROCESS FOR THE ENZYMATIC PRODUCTION OF GLP-2 (1-34) AND GLP-2 (1-33) PEPTIDES
AU2003239894A1 (en) 2002-05-24 2003-12-12 Restoragen Inc. Methods and constructs for high yield expression of clostripain
WO2005067368A2 (en) 2003-11-21 2005-07-28 Nps Allelix Corp. Production of glucagon like peptide 2 and analogs
WO2006028634A2 (en) * 2004-09-01 2006-03-16 Vijay Ramakrishnan Site specific pegylation of broadly-neutralizing antibodies against hepatitis c virus and their use in the treatment of chronic hcv infections
US7592315B2 (en) 2004-11-02 2009-09-22 Schering Corporation Peptide viral entry inhibitors
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
BRPI0823197A2 (pt) 2008-10-05 2015-06-23 Univ Leland Stanford Junior Anticorpos contra hepatite c e aplicações dos mesmos
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
US20130129676A1 (en) * 2010-05-25 2013-05-23 Universite De Strasbourg Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP4257134A3 (en) 2015-06-25 2024-01-24 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
AU2021256402A1 (en) * 2020-04-12 2022-11-17 Aethlon Medical, Inc. Devices and methods for treating a coronavirus infection and symptoms thereof
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
US6538114B1 (en) * 1996-04-19 2003-03-25 Karolina Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US6747136B2 (en) 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
CA2305715A1 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Host derived proteins binding hcv: medical, diagnostic and purification use
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4958773B2 (ja) * 2005-06-02 2012-06-20 松森　　昭 Ｃ型肝炎ウイルス感染の診断、予防および治療方法
JP2010501594A (ja) * 2006-08-25 2010-01-21 ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド 組換えｈｃｖｅ２糖タンパク質
JP2014240427A (ja) * 2006-08-25 2014-12-25 ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド 組換えｈｃｖｅ２糖タンパク質
JP2010518854A (ja) * 2007-02-21 2010-06-03 ユニバーシティー オブ マサチューセッツ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
US8551484B2 (en) 2007-02-21 2013-10-08 University Of Massachusetts Human antibodies against hepatitis C virus (HCV) and uses thereof
JP5608087B2 (ja) * 2008-09-30 2014-10-15 東レ株式会社 Ｃ型肝炎ウイルスのエンベロープタンパク質２に結合する抗体及びそれを用いたｃ型肝炎ウイルスの遺伝子型の同定方法

Also Published As

Publication number Publication date
EP1127170A4 (en) 2005-04-27
EP1127170A1 (en) 2001-08-29
AU1462300A (en) 2000-05-22
US6692908B1 (en) 2004-02-17
WO2000026418A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
JP2002528140A (ja) ヒトｐａｎ−ｈｃｖヒトモノクローナル抗体
Burioni et al. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments
CA2065287C (en) New hcv isolates
JP2810022B2 (ja) Ｎａｎｂｖの診断用薬
US6210675B1 (en) PT-NANB hepatitis polypeptides
JP3645904B2 (ja) Ｃ型肝炎ウイルスの型の分類方法およびそこで使用する試薬
Allander et al. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins
JP2005531286A (ja) ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片
US7091324B2 (en) Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
US7034108B1 (en) Mimotopes of hypervariable region 1 of the E2 glycoprotein of HCV and uses thereof
JP3061258B2 (ja) 非ａ非ｂ非ｃ非ｄ非ｅ型肝炎試薬及びそれらの使用方法
JP2006504645A (ja) 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療
CA2101534C (en) Monoclonal antibodies to putative hcv envelope region and methods for using same
JPH06510191A (ja) Ｎｓ１に対する組換え抗原を利用したｃ型肝炎アッセイ
JPH06507552A (ja) 肝炎疾患の診断において有用なｄｎａ配列及びコードされたポリペプチド
WO2002059340A1 (en) Immunopolypeptides to hepatitis c virus
JPH09511137A (ja) 非ａ非ｂ非ｃ非ｄ非ｅ型肝炎試薬及びそれらの使用方法
JPH08504421A (ja) Ｈｃｖのｃ３３領域由来のペプチド、該ペプチドに対する抗体及びｈｃｖの検出方法
JPH07135981A (ja) 非ａ非ｂ型肝炎ウイルス遺伝子に由来するｄｎａ及び構成ポリペプチド
Foung et al. Human Monoclonal Antibody to Hepatitis C
JPH0568563A (ja) Ｃ型肝炎ウイルス遺伝子およびその利用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091104

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20091104

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20091104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091104

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100202